Pharmx Technologies reinstated to ASX quotation
Key points
- Pharmx Technologies' trading suspension lifted after announcement on NDSS agreement renewal
- Company to resume trading on the ASX immediately
- NDSS agreement renewal secures ongoing revenue stream
Full summary
Pharmx Technologies Ltd (ASX: PHX) has been reinstated to trading on the Australian Securities Exchange (ASX) following the release of an announcement regarding the renewal of its long-standing National Diabetes Services Scheme (NDSS) agreement. The suspension of trading in Pharmx's securities has been lifted immediately, allowing the company to resume trading on the ASX. The NDSS agreement renewal secures an ongoing revenue stream for Pharmx, which is a key component of the company's business operations. This announcement provides investors with confidence in Pharmx's financial stability and future prospects as it continues to serve the diabetes care market through its products and services.
Summary generated by a large language model. Please interpret with care.